Evidence map›Paper›PMID 38716551›Full record

ReviewCurrent pharmaceutical biotechnology2025

Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer.

Romulo R Macadangdang, Rutvi Agrawal, Bharat Bhushan, Akash Garg, Kuldeep Singh, Shivendra Kumar, Atul Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Romulo R MacadangdangDepartment of Nursing, College of Allied Health, National University, Manila, Philippines.ORCID 0000-0003-0994-7084
Rutvi AgrawalDepartment of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.ORCID 0000-0002-1276-306X
Bharat BhushanDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0002-0691-8408
Akash GargDepartment of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.ORCID 0000-0002-6127-7412
Kuldeep SinghDepartment of Pharmacology, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.ORCID 0000-0001-8772-8157
Shivendra KumarDepartment of Pharmacology, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.ORCID 0000-0002-2287-6981
Atul KumarDepartment of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.ORCID 0009-0006-3617-3431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a significant global health challenge, necessitating innovative approaches to enhance the efficacy and specificity of therapeutic interventions while minimizing adverse effects on healthy tissues. Nanotechnology has emerged as a promising avenue in cancer treatment, offering novel strategies for targeted drug delivery. Nanoparticles, liposomes, and polymer-based systems have played pivotal roles in revolutionizing cancer therapy. Nanotechnology possesses unique physicochemical properties, enabling efficient encapsulation of therapeutic agents and controlled and prolonged release at tumour sites. Advancement in formulations using nanotechnology has made it possible to make multifunctional systems that respond to the microenvironment of a tumour by releasing payloads in response to changes in pH, temperature, or enzymes. Stimuli-responsive polymers can release drugs in response to external cues, enabling site-specific drug release and minimizing systemic exposure. This review explores recent studies and preclinical trials that show how nanoparticles, liposomes, and polymerbased systems could be used to treat cancer, discussing challenges such as scalability, regulatory approval, and potential toxicity concerns along with patents published recently.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanotechnologyNeoplasmsAnimalsHumansLiposomesNanoparticlesPolymersAntineoplastic AgentsLiposomesPolymersdendrimers.liposomesnanoparticlesNanotechnologypolymer-based systemstargeted drug deliverytherapeutic outcomes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.